Navigation Links
Halozyme's Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase 2 Study Results Presented at ADA 2012
Date:6/11/2012

PHILADELPHIA, June 11, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced results from a Phase 2 study of prandial insulin formulations, which include the Company's recombinant human hyaluronidase (rHuPH20) enzyme, in patients with Type 1 diabetes. The study met its primary endpoint of A1C non-inferiority (A1C is a measure of average blood sugar over three months). Further, data from the study indicated that rHuPH20 reduced postprandial glycemic excursions, as well as significantly reduced hypoglycemic events. These findings were presented in an oral presentation at the 72nd Scientific Sessions of the American Diabetes Association (ADA) on Monday, June 11 from 6:15 - 6:30 PM EDT.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

"There is a real need for faster-acting mealtime insulins. By accelerating the absorption and action of prandial insulins, rHuPH20 may help reduce mealtime glucose fluctuations that make managing diabetes difficult," said Irl B. Hirsch, M.D., Professor of Medicine, Diabetes Treatment and Teaching Chair, University of Washington School of Medicine. "This faster-in, faster-out profile may also attenuate the risk of hypoglycemia. In this study, improved control of mealtime glucose significantly reduced hypoglycemic events in patients receiving treatments with the rHuPH20 enzyme. The data further indicated that Halozyme's ultrafast insulin formulations moderate glucose swings, thus more closely mimicking the effects of endogenous insulin and, if approved, could ultimately help patients with diabetes live healthier lives."

The study compared two rapid acting insulin analog products (lispro or aspart), formulated with rHuPH20 (lispro-PH20 and aspart-PH20, each an Analog-PH20), to an active comparator (lispro alone). The study me
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Biodels Intellectual Property Position Strengthened for Ultra-Rapid-Acting Insulin Programs by Notice of Intent to Grant from European Patent Office
2. Glytec Adds Pediatric Insulin Dosing to its IV and SubQ FDA Clearances
3. Valeritas Inc. Selects dLifes New Diabetes Patient Engagement Solution For Valeritas V-go Disposable Insulin Delivery Device
4. Biodel Obtains Exclusive License to Aegis Therapeutics Technologies for Development and Commercialization of Glucagon Pharmaceutical Formulations
5. Stereotaxis Reports Improved First Quarter 2012 Financial Results
6. Mindray Medical to Acquire Controlling Stake in Hangzhou Optcla Medical Instrument
7. Celleration, Inc. Announces First Patient Enrollment in In-Balance VLU Randomized Control Trial
8. Accident Fund Holdings Aims to Improve Control of Drug Utilization and Quality of Care with Change in Pharmacy Benefit Manager
9. DebMed® to Debut Benefits of Worlds First Electronic Hand Hygiene Compliance Monitoring System Using the WHO Five Moments at Annual Infection Control Conference
10. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
11. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)...  Luminex Corporation (Nasdaq: LMNX ) today announced that ... 2013 on Monday, February 3, 2014. A press release announcing ... trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... highlights and financial results for the fourth quarter and twelve ...
(Date:1/14/2014)... Healthcare Services, Inc. ("DHS"), a portfolio company of GMH Ventures ... Equipment, Inc. ("Progressive") of Clarion, PA ... not disclosed. Progressive is a full service ... sleep, mobility, and respiratory products to customers in the western ...
(Date:1/14/2014)... PLYMOUTH, Minn. , Jan. 14, 2014   NuAire , a ... come to agreement with Hitachi Koki of ... centrifuges in North America . NuAire will utilize ... and Canada to offer assistance ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
... NEW YORK, Nov. 3, 2010 Coronado Biosciences, ... oncology drug development, announced completion of a series ... gross proceeds to the Company of approximately $21.6 ... from these financings for general corporate purposes, including ...
... Nov. 3, 2010 Telik, Inc. (Nasdaq: TELK ... $0.09 per share, for the third quarter ended September 30, ... $0.11 per share, for the comparable period in 2009. ... costs and expenses were $4.7 million, compared with $6.2 million in ...
Cached Medicine Technology:Coronado Biosciences, Inc. Announces Completion of Financings, Management Changes and Development Update 2Coronado Biosciences, Inc. Announces Completion of Financings, Management Changes and Development Update 3Telik Announces Third Quarter 2010 Financial Results 2Telik Announces Third Quarter 2010 Financial Results 3
(Date:4/17/2014)... -- The world is less than 40 years away ... for people and governments, according to a top scientist ... first time in human history, food production will be ... land, water and energy," said Dr. Fred Davies, senior ... "Food issues could become as politically destabilizing by 2050 ...
(Date:4/17/2014)... 17, 2014While 94 per cent of Canadians surveyed said ... newborns for a specific number of genetic conditions, only ... participate in screening that would sequence their newborns, genomes.,Most ... in their first day or two of life in ... their heels and tested for about five to 54 ...
(Date:4/17/2014)... Vice-Chancellor, Professor Patrick Johnston, whose work has transformed cancer ... Fellow of the European Academy of Cancer Sciences., The ... advisory body of highly distinguished oncologists and cancer researchers ... by cancer in Europe. , Professor Johnston, whose leadership ... from the bottom of the UK league table to ...
(Date:4/17/2014)... from LSTM have called for more research to ... in children in sub-Saharan Africa. In a paper ... Professor Russell Stothard, working with colleagues in the ... Reserve University, in Cleveland Ohio, University of Cambridge ... research into the joint burden of HIV/AIDS and ...
(Date:4/16/2014)... April 15, 2014 The Translational Genomics Research ... their annual Founders Dinner for their support of TGen,s ... took place March 28 in Scottsdale. , Catherine Ivy, ... Foundation, received TGen,s John S. McCain Leadership Award, named ...
Breaking Medicine News(10 mins):Health News:Food shortages could be most critical world issue by mid-century 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3Health News:More research called for into HIV and schistosomiasis coinfection in African children 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2
... 2011 Metabolomx, a diagnostic company focused on the ... breath, today announces publication of results from the first ... detect lung cancer and differentiate between types of lung ... the Cleveland Clinic and led by Dr. Peter Mazzone, ...
... patients in a New England Journal of Medicine ... recovered from hip surgery, according to new research co-authored ... findings could immediately change the way such patients are ... strengthen patients weakened by anemia, improving their chances at ...
... been diagnosed with locally-advanced pancreatic cancer in the United ... for these patients whose tumor has grown beyond the ... 20 years, numerous treatment regimens have been evaluated for ... being the current standard approach. However, the median survival ...
... , WEDNESDAY, Dec. 14 (HealthDay News) -- Alcohol ... more of them are using marijuana and don,t believe it,s ... by the U.S. National Institute on Drug Abuse and the ... students in grades eight, 10 and 12 at 400 public ...
... Amanda Gardner HealthDay Reporter , WEDNESDAY, Dec. 14 ... cholesterol levels, may one day also prove useful in combating ... the Journal of Infectious Diseases finds that patients ... were taking a statin, compared with their peers who weren,t ...
... News) -- In the aftermath of a deadly crash in ... Transportation Safety Board is recommending a nationwide ban on drivers, ... emergencies. According to media reports, the board was meeting ... occurred last year in Gray Summit, Mo. The NTSB ...
Cached Medicine News:Health News:Metabolomx test detects lung cancer from breath 2Health News:Metabolomx test detects lung cancer from breath 3Health News:University of Maryland finds restricting post-surgery blood transfusion is safe for some hip patients 2Health News:University of Maryland finds restricting post-surgery blood transfusion is safe for some hip patients 3Health News:RTOG initiates a phase I trial testing the therapy ganitumab for locally advanced pancreatic cancer 2Health News:Alcohol Use Down, Pot Use Up Among U.S. Teens 2Health News:Could Statins Help Those Hospitalized With Flu? 2Health News:U.S. Safety Board Urges Nationwide Ban on Drivers' Use of Cellphones 2
This lens gives the appearance of mystery and mayhem behind the blackest of eyes....
Silicone tip cannula angled at 7 mm, sterile, disposable (bx/10)....
Medpor Sphere Inserter. The Inserter is provided as a value added item to Medpor Orbital Implants....
Reusable cannula with .90 mm (20 g) shaft, tapering to .30 mm (30 g). Angled 125 3 mm from tip and flattened for easy insertion into the subretinal space....
Medicine Products: